ArticleCureus2024
Metastatic Calcinosis Cutis: Unusual Locations in End-Stage Renal Disease.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic calcinosis cutis is a rare consequence of end-stage renal disease (ESRD), which occurs due to elevated levels of serum phosphorus and abnormal phosphate and calcium metabolism, leading to the precipitation and deposition of calcium in the cutaneous and subcutaneous tissues. This paper reports the case of a 33-year-old male with ESRD and a six-year history of hemodialysis treatment who presented with multiple areas of gradually enlarging, lobulated calcified soft tissue masses observed bilaterally at the level of the acromioclavicular joint and superomedial aspect of the right thigh, extensively involving the perineal region and the right superior anterior chest wall. The unique character of this case is the rare involvement of the sternoclavicular joint and the symphysis pubis. The relevant laboratory findings included elevated levels of serum phosphorus, blood urea nitrogen, and creatinine, which were consistent with metastatic calcinosis cutis as a consequence of ESRD. The treatment of secondary calcinosis cutis primarily includes low-calcium and low-phosphorus diets, dialysates, and phosphate binders, except aluminum-containing binders, which were advised for this patient. Imaging is the mainstay for the diagnosis of calcinosis cutis, and as metastatic calcinosis cutis is an infrequent and debilitating consequence of ESRD, prompt diagnosis and appropriate treatment are paramount.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.